Bruker Provides Preliminary Q4 2025 Revenue and Positive FY2026 EPS & Margin Outlook
Summary
Bruker Corporation announced preliminary Q4 2025 revenue expectations and a positive outlook for full-year 2026, projecting double-digit non-GAAP EPS growth and significant operating margin expansion.
Key Events
-
Preliminary Q4 2025 Revenue
Bruker expects Q4 2025 revenue to be between $965 million and $970 million.
-
Strong Book-to-Bill Ratio
The Bruker Scientific Instruments segments reported a book-to-bill ratio above 1.0 for Q4 2025, indicating robust order intake.
-
Positive FY2026 Outlook
The company anticipates full-year 2026 organic revenue growth of flat to low-single digits, non-GAAP organic operating margins to expand by 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits.
Analysis
Bruker's preliminary financial update, delivered at the J.P. Morgan Healthcare Conference, provides investors with key insights into its near-term performance and future trajectory. The projected double-digit non-GAAP earnings per share growth and substantial operating margin expansion for 2026 indicate a strong focus on profitability and operational efficiency. While organic revenue growth is expected to be modest, the positive book-to-bill ratio for its Scientific Instruments segments suggests healthy demand. Investors will likely view the margin and EPS guidance favorably, despite the preliminary nature of these estimates.
At the time of this filing, BRKR was trading at $54.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8B. The 52-week trading range was $28.53 to $64.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.